RLAY: Bull Flag detected on 27 Aug 2026

RLAY has formed a bull flag pattern with excellent structure scoring (15.0/15) on elevated volume, signaling institutional accumulation. The stock is trading at $19.46, having bounced from key support at $17.71 and approaching resistance at $20.79. Volume ratio of 1.35x above 20-day average confirms above-average participation. At 49.18 RSI, momentum is neutral without overbought conditions. The pattern suggests a measured move target of $20.10, a modest but clean setup. Win probability scores 75.13%, reflecting strong historical breakout success for this structure.

Relay Therapeutics announced Q2 2026 results on August 6, 2026, with investors watching for updates on its lead asset zovegalisib. Recent earnings-beat optimism and strong share price run suggest expectations are already elevated. The company received FDA Breakthrough Therapy designation for zovegalisib in PIK3CA-mutant, HR+/HER2- advanced breast cancer, the Phase 3 ReDiscover-2 trial population. A fresh $175 million equity raise and expanded share authorization underscore that Relay is still funding an unprofitable model, with future financing and trial risk firmly in view. The biotech sector regime is bullish (0.93 score), providing tailwinds, though broader market regime is bearish (-0.21). The stock has surged 34.86% in three months, positioning this pattern within an uptrend despite recent weekly weakness.

A successful breakout above $20.79 resistance would project to the conservative target of $20.10, with potential extension to $21-22 based on flag depth. Volume confirmation is critical—breakout candles should show volume exceeding the current 2.94M share average. The setup invalidates below key support at $17.71, representing a 9% downside risk from current price. The 75.13% win probability indicates this pattern has historically resolved higher three-quarters of the time. Given beta of 0.92 and 5.19% ATR volatility, price swings will be moderate relative to broader biotech moves.

The Phase 3 trajectory for zovegalisib and broader oncology pipeline trial execution remain the main catalyst, introducing binary clinical risk. Elevated expectations from the recent earnings beat can amplify even modest data surprises, creating downside volatility if August 6 results disappoint—particularly on trial enrollment or safety signals. The company is unprofitable with ongoing cash burn, increasing reliance on equity financing that could dilute shareholders. MACD histogram is negative (-0.0933), suggesting momentum may be cooling. Biotech sector volatility and single-drug pipeline concentration add execution risk. No imminent catalysts beyond trial data could cause pattern to consolidate sideways rather than break cleanly higher.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.